Alere Settles False Claims Act Allegations for $33 Million

| Printer friendly version

The United States Department of Justice announced that Alere Inc. and its subsidiary, Alere San Diego, reached a settlement agreement with the United States government for $33.2 million over allegations that Alere had violated the False Claims Act.  According to Healthcare Finance, the settlement did not include any admission of actual liability on Alere’s part.

The False Claims Act was passed “to protect taxpayer dollars from fraud and abuse and to allow private citizens to join the effort,” according to Maureen R. Dixon, Special Agent in Charge for the U.S. Department of Health and Human Services Office of Inspector General in Philadelphia. The lawsuit alleged that, between January 2006 and March 2012, Alere caused hospitals to submit false claims to Medicare, Medicaid, and other federal healthcare programs by knowingly selling materially unreliable point-of-care diagnostic testing devices under the trade name Triage®.

According to a press release, the devices, which were generally used in time-sensitive emergency room settings, produced erroneous results and had the potential to create false positives and false negatives. Alere allegedly became aware of the erroneous results through customer complaints but failed to take appropriate action until the Food and Drug Administration prompted a product recall in 2012.

As a result of the settlement, the federal government will receive $28,378,893, and individual states will receive $4,860,779. Amanda Wu, a former senior quality control analyst for Alere, filed the current lawsuit on behalf of the United States under the whistle blower provision of the False Claims Act and will receive approximately $5.6 million, per the provisions of the False Claims Act.

Albert Sueiras
Albert Sueiras is an associate in the Orange County office. Mr. Sueiras received his bachelor's degree in Biomedical Engineering, cum laude, from the University of Miami and also received his master's degree in Biomedical Engineering, cum laude, from the University of Florida. He received his J.D. from the University of Florida Levin College of Law, where he was a member of Phi Delta Phi. During law school, Mr. Sueiras externed at the United States Patent and Trademark Office within Art Unit 3733, focusing on patent examination of orthopedic surgical instrumentation. Mr. Sueiras also participated in a patent prosecution externship at Banyan Biomarkers, Inc. in Alachua, Florida, a firm specializing in the discovery of biomarkers for traumatic brain injury and neurotoxicity. Mr. Sueiras worked as a summer associate at the firm in 2015 and joined the firm in 2016.
Click here to read full bio
View all posts published by Albert Sueiras »

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.